Related posts
Nervous markets await NvidiaThis summary was created by AI, based on 9 opinions in the last 12 months.
Vertex Pharmaceuticals Inc. (VRTX-Q) has garnered a mix of opinions from experts following its recent performance. Many are enthusiastic about the company's pain medication, particularly highlighting its non-addictive properties and the excitement surrounding upcoming FDA approvals. Some analysts note that despite a strong quarter and a significant rise in stock value—up 20% this year—the stock experienced a pullback, which they attribute to profit-taking. There are also concerns regarding negative free cash flow heading into 2024. Overall, while there are challenges, most experts maintain a positive outlook, emphasizing the strength of Vertex's pipeline and its established position in the cystic fibrosis market.
Vertex Pharmaceuticals Inc. is a American stock, trading under the symbol VRTX-Q on the NASDAQ (VRTX). It is usually referred to as NASDAQ:VRTX or VRTX-Q
In the last year, 6 stock analysts published opinions about VRTX-Q. 2 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Vertex Pharmaceuticals Inc..
Vertex Pharmaceuticals Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Vertex Pharmaceuticals Inc..
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
6 stock analysts on Stockchase covered Vertex Pharmaceuticals Inc. In the last year. It is a trending stock that is worth watching.
On 2025-04-25, Vertex Pharmaceuticals Inc. (VRTX-Q) stock closed at a price of $493.84.
A strong performer in this market, not pulling back. Everybody is excited over their pain drug, and other drugs in the pipeline as well.